2004
DOI: 10.1038/sj.leu.2403532
|View full text |Cite
|
Sign up to set email alerts
|

Raf and VEGF: emerging therapeutic targets in Kaposi's sarcoma-associated herpesvirus infection and angiogenesis in hematopoietic and nonhematopoietic tumors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
27
0

Year Published

2005
2005
2017
2017

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 36 publications
(28 citation statements)
references
References 91 publications
(131 reference statements)
1
27
0
Order By: Relevance
“…FGF-2, VEGF, and VEGFR-1 appear to have an equivalent distribution in corresponding CCS structures, and this finding agrees with the known autocrine and paracrine roles of the two factors and their synergic induction of angiogenesis (Costa et al, 2004;Hamden et al, 2005;Bikfalvi et al, 1997). Of particular interest is the finding that VEGF and VEGFR-1 are expressed at the level of the same territory.…”
Section: Filopodia and Angiogenic Signalssupporting
confidence: 78%
“…FGF-2, VEGF, and VEGFR-1 appear to have an equivalent distribution in corresponding CCS structures, and this finding agrees with the known autocrine and paracrine roles of the two factors and their synergic induction of angiogenesis (Costa et al, 2004;Hamden et al, 2005;Bikfalvi et al, 1997). Of particular interest is the finding that VEGF and VEGFR-1 are expressed at the level of the same territory.…”
Section: Filopodia and Angiogenic Signalssupporting
confidence: 78%
“…PD98059 is a commonly used small molecule inhibitor that inhibits both the phosphorylation and activation of MEK. 18 We found PD98059 to significantly lower phosphorylation of ERK1/2 in HFF, BCBL-1, BC-1, BC-2, BCP-1, and BJAB cells ( Figure 1C). PD98059 treatment lowered ERK1/2 phosphorylation in a dosedependent manner but did not lower the level of total ERK1/2 ( Figure 1C).…”
mentioning
confidence: 88%
“…Liu et al 57 provided further evidence that VEGF is a critical mediator of angiogenesis stimulation by vIL-6 in vitro and in vivo. Hamden et al 58 showed that Raf regulates the expression of a variety of growth factors including VEGF. On the other hand, Wang et al 59 demonstrated that K1, the transmembrane glycoprotein that is encoded by the first open reading frame of KSHV, is responsible of the VEGF upregulation mediated at the transcriptional level by VEGF promoter activation.…”
Section: Discussionmentioning
confidence: 99%